EBioMedicine

EBioMedicine is a gold open access journal that publishes translational biomedical research spanning the pathway from basic disease mechanisms to clinical application and human health.《电子生物医学》（EBioMedicine）是一份金色开放获取期刊，发表从基础疾病机制到临床应用与人类健康的转化生物医学研究。

Scope

The journal's stated aim is to publish original research that elucidates or aims to modify disease pathways and mechanisms, with its official scope covering:刊物官方宗旨为发表阐明或旨在干预疾病通路与机制的原创研究，官方声明的征稿范围包括：

• Disease mechanisms: basic research on the molecular and cellular pathways underlying human disease, including genetics, epigenetics, cell biology, immunology, microbiology, and the determinants of health and disease.疾病机制： 人类疾病分子与细胞通路的基础研究，涵盖遗传学、表观遗传学、细胞生物学、免疫学、微生物学以及健康与疾病的决定因素。
• Therapeutic discovery: research on the discovery and characterisation of new therapeutic targets and treatments, including preclinical studies with demonstrable relevance to human health and disease.治疗发现： 新治疗靶点与疗法的发现与表征研究，包括与人类健康和疾病具有明确相关性的临床前研究。
• Clinical and translational: clinical studies that advance understanding of disease mechanisms and target pathways, together with translational research that bridges laboratory findings and clinical practice across all biomedical disciplines.临床与转化： 增进对疾病机制与靶点通路理解的临床研究，以及在所有生物医学学科中衔接实验室发现与临床实践的转化研究。
• Article types: original research papers, reviews, commentaries, and opinion pieces, with a priority on findings that are relevant to human health and that demonstrate translational potential.栏目设置： 接受原创研究论文、综述、述评与观点文章，优先发表与人类健康相关且具有转化潜力的研究发现。

History

• Founding: the journal was launched in November 2014 by Elsevier as a collaboration between Cell Press and The Lancet, designed to connect basic biological research with clinical medicine under a fully open access model.创刊： 该刊 2014 年 11 月由爱思唯尔创刊，是细胞出版社与《柳叶刀》合作的产物，旨在以完全开放获取模式连接基础生物学研究与临床医学。
• Editorial heritage: from its launch the journal drew on the editorial expertise of both The Lancet and Cell Press, combining The Lancet's strengths in clinical research and public health with Cell Press's strengths in molecular and cellular biology.编辑传承： 自创刊起该刊即依托《柳叶刀》与细胞出版社的编辑专长，将《柳叶刀》在临床研究与公共卫生方面的优势与细胞出版社在分子与细胞生物学方面的优势相结合。
• Translational identity: over its first decade the journal established itself as a venue for two-way translational research, valuing both preclinical work that informs clinical questions and clinical studies that refine mechanistic understanding.转化定位： 在创刊后的第一个十年里，该刊确立了双向转化研究平台的定位，既重视为临床问题提供信息的临床前工作，也重视完善机制理解的临床研究。

Editors

The journal follows the in-house editorial model shared by The Lancet family of journals, with professional editors rather than a single academic editor-in-chief handling peer review and publication decisions:该刊采用《柳叶刀》系列期刊共有的内部编辑模式，由专业编辑而非单一学术主编负责同行评审与发表决定：

• In-house editorial team: the journal is managed by a team of professional in-house editors based in London, each with a doctoral background in a biomedical field and responsibility for a defined subject area within translational medicine.内部编辑团队： 该刊由驻伦敦的专业内部编辑团队管理，每位编辑均具备生物医学领域博士背景，负责转化医学中一个特定的学科方向。
• Advisory board: the in-house editors are supported by an international advisory board of biomedical researchers who provide guidance on scope, emerging topics, and the evaluation of high-impact submissions.顾问委员会： 内部编辑团队得到由生物医学研究者组成的国际顾问委员会支持，为刊物范围、新兴议题以及高影响力投稿的评估提供指导。
• Editorial process: submissions are first assessed by an in-house editor for fit and novelty, and those that pass this initial screen are sent for external peer review before a final editorial decision is made.编辑流程： 投稿先由内部编辑评估适配性与新颖性，通过初筛的稿件送外部同行评审后再做最终编辑决定。